EP2008100A4 - Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement - Google Patents

Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement

Info

Publication number
EP2008100A4
EP2008100A4 EP07755712A EP07755712A EP2008100A4 EP 2008100 A4 EP2008100 A4 EP 2008100A4 EP 07755712 A EP07755712 A EP 07755712A EP 07755712 A EP07755712 A EP 07755712A EP 2008100 A4 EP2008100 A4 EP 2008100A4
Authority
EP
European Patent Office
Prior art keywords
patient
determining
response sensitivity
antibody profiling
profiling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07755712A
Other languages
German (de)
English (en)
Other versions
EP2008100A2 (fr
Inventor
Wolfgang Hueber
William H Robinson
Lawrence Steinman
Paul J Utz
Mark Genovese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP2008100A2 publication Critical patent/EP2008100A2/fr
Publication of EP2008100A4 publication Critical patent/EP2008100A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
EP07755712A 2006-04-18 2007-04-18 Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement Withdrawn EP2008100A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79302906P 2006-04-18 2006-04-18
PCT/US2007/009537 WO2007123976A2 (fr) 2006-04-18 2007-04-18 Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement

Publications (2)

Publication Number Publication Date
EP2008100A2 EP2008100A2 (fr) 2008-12-31
EP2008100A4 true EP2008100A4 (fr) 2009-12-16

Family

ID=38625581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07755712A Withdrawn EP2008100A4 (fr) 2006-04-18 2007-04-18 Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement

Country Status (3)

Country Link
US (2) US20080026485A1 (fr)
EP (1) EP2008100A4 (fr)
WO (1) WO2007123976A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005075414A1 (ja) * 2004-02-04 2007-10-11 公立大学法人横浜市立大学 ペプチジルアルギニンデイミナーゼ４阻害剤
WO2007009613A1 (fr) * 2005-07-16 2007-01-25 Merck Patent Gmbh Procede de mesure de la phosphorylation des tyrosine kinases
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
US7454294B2 (en) * 2007-01-12 2008-11-18 Kapke Gordon F Monitoring Z-values for clinical data interpretation
EP2056110A1 (fr) 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha
EP2245459A1 (fr) 2008-01-23 2010-11-03 Herlev Hospital Ykl-40 en tant que marqueur général pour une maladie non spécifique
US20090240695A1 (en) * 2008-03-18 2009-09-24 International Business Machines Corporation Unique cohort discovery from multimodal sensory devices
US8335698B2 (en) * 2008-03-24 2012-12-18 International Business Machines Corporation Optimizing cluster based cohorts to support advanced analytics
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
US8338188B2 (en) * 2008-05-14 2012-12-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for the diagnosis of rheumatoid arthritis
AU2009291312A1 (en) 2008-09-15 2010-03-18 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
MX2011003352A (es) * 2008-09-30 2011-05-02 Genentech Inc Marcadores biologicos predictivos de la respuesta de la artritis reumatoide a antagonistas de linfotoxina.
US9063148B2 (en) * 2008-10-22 2015-06-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicince, Inc. Immunoassays for citrullinated proteins
EP2385839B1 (fr) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Compositions thérapeutiques pour le traitement de troubles de la cornée
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US20100204058A1 (en) * 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
WO2011014349A1 (fr) * 2009-07-28 2011-02-03 Centocor Ortho Biotech Inc. Marqueurs sériques pour la prédiction de la réponse clinique à des anticorps anti-tnfα chez des patients atteints de psoriasis arthropathique
CA2777800C (fr) * 2009-10-15 2019-11-12 Crescendo Bioscience Biomarqueurs et procedes de mesure et de surveillance de l'activite d'une maladie inflammatoire
CA2928846A1 (fr) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anticorps anti-clusterine et fragments de liaison de l'antigene et leur utilisation dans la reduction du volume d'une tumeur
US20110129129A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related data for determining a disease signature
US9271651B2 (en) * 2009-11-30 2016-03-01 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using patient related time trend data
US20110129130A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related time trend data
US20110129131A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related time trend data and disease profiles
EP2336769A1 (fr) * 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Test pour différencier les troubles rhumatismaux des troubles non rhumatismaux
US20130040844A1 (en) * 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (fr) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Modulation du ccr3 pour le traitement de déficiences associées au vieillissement, et compositions utilisées pour cette modulation
US20130246097A1 (en) * 2010-03-17 2013-09-19 Howard M. Kenney Medical Information Systems and Medical Data Processing Methods
JP5786020B2 (ja) * 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012051519A2 (fr) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarqueurs d'une lésion cérébrale
WO2012061620A1 (fr) * 2010-11-04 2012-05-10 Genentech, Inc. Procédés de traitement, de diagnostic et de surveillance de la polyarthrite rhumatoïde
US20150218546A1 (en) 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP2707389B1 (fr) 2011-05-12 2019-10-30 The Johns Hopkins University Réactifs de dosage pour kit de diagnostic de la neurogranine
WO2012163768A1 (fr) * 2011-05-27 2012-12-06 Nordic Bioscience A/S Détection de peptides diagnostiques
US20140227303A1 (en) * 2011-06-29 2014-08-14 Viracor-Ibt Laboratories Methods for diagnosing and monitoring diseases or conditions using disease modified biomolecules and measurement of a functional immune response
WO2013077864A1 (fr) 2011-11-22 2013-05-30 Robert Bosch Gmbh Méthode d'essai de confiance auto-référencé
CA2862739A1 (fr) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer
WO2013138509A1 (fr) * 2012-03-13 2013-09-19 The Johns Hopkins University Protéines cérébrales et neurologiques citrullinées en tant que biomarqueurs de lésions cérébrales ou de neurodégénérescence
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
EP3022322A4 (fr) 2013-07-17 2017-05-17 The Johns Hopkins University Dosage de biomarqueurs multiprotéiniques pour la détection et l'issue de lésions cérébrales
US9387246B2 (en) 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
JP6220222B2 (ja) * 2013-10-28 2017-10-25 シスメックス株式会社 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3079708A4 (fr) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Méthodes et compositions pour traiter des états associés au vieillissement
CA2943821A1 (fr) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarqueurs et procedes de mesure et de surveillance de l'activite de l'arthrite idiopathique juvenile
WO2015191423A1 (fr) * 2014-06-09 2015-12-17 Crescendo Bioscience Biomarqueurs et procédés d'évaluation de la réponse à un traitement de maladie inflammatoire
JP2017523437A (ja) 2014-06-10 2017-08-17 クレッシェンド バイオサイエンス インコーポレイテッド 体軸性脊椎関節炎の疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
MX2017004742A (es) * 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
JPWO2016199180A1 (ja) * 2015-06-09 2018-04-12 国立大学法人大阪大学 生物学的製剤による関節リウマチの治療効果の予測判定方法
PT3307296T (pt) 2015-06-15 2022-01-07 Univ Leland Stanford Junior Timp2 para uso no tratamento de condições associadas ao envelhecimento
WO2017021552A1 (fr) * 2015-08-06 2017-02-09 Novimmune Sa Procédés et compositions permettant d'identifier des populations de patients pour le diagnostic et le traitement de troubles dépendant de tlr4
ES3041639T3 (en) 2015-09-29 2025-11-13 Univ California Biomarkers and methods for assessing psoriatic arthritis disease activity
WO2017058999A2 (fr) 2015-09-29 2017-04-06 Crescendo Bioscience Biomarqueurs et méthodes d'évaluation de la réponse à l'arrêt d'une thérapie contre les maladies inflammatoires
WO2017087634A1 (fr) * 2015-11-17 2017-05-26 The Regents Of The University Of Colorado, A Body Corporate Évaluations multiplexes innovantes pour diagnostiquer ou évaluer des maladies ou des désordres chez les mammifères
US10612075B2 (en) * 2015-12-28 2020-04-07 PathogenDX Inc Microarray based multiplex pathogen analysis and uses thereof
US11542498B2 (en) * 2015-12-28 2023-01-03 Pathogendx, Inc. Microarray based multiplex pathogen analysis and uses thereof
US10299751B2 (en) 2016-03-16 2019-05-28 General Electric Company Systems and methods for color visualization of CT images
US10475217B2 (en) 2016-03-16 2019-11-12 General Electric Company Systems and methods for progressive imaging
EP3426265B1 (fr) 2016-04-28 2021-09-22 Alkahest, Inc. Utilisation de fractions de plasma sanguin contre la croissance et la progression tumorale
WO2017223117A1 (fr) 2016-06-20 2017-12-28 Healthtell Inc. Méthodes pour le diagnostic et le traitement de maladies auto-immunes
WO2017223116A2 (fr) 2016-06-20 2017-12-28 Healthtell Inc. Procédés pour le diagnostic différentiel de maladies auto-immunes
IL304946A (en) 2016-08-18 2023-10-01 Alkahest Inc Blood plasma fractions as a treatment for cognitive disorders associated with aging
WO2018065300A1 (fr) * 2016-10-04 2018-04-12 F. Hoffmann-La Roche Ag Système et procédé d'identification d'un classificateur synthétique
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CN110168370A (zh) 2016-11-11 2019-08-23 健康之语公司 用于鉴定候选生物标志物的方法
JP2018163071A (ja) * 2017-03-27 2018-10-18 京都府公立大学法人 関節リウマチに関するペプチドマーカー
US11382907B2 (en) 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
BR112019022402A2 (pt) 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス，インコーポレーテッド 寛容原性リポソーム及びその使用方法
US10146914B1 (en) * 2018-03-01 2018-12-04 Recursion Pharmaceuticals, Inc. Systems and methods for evaluating whether perturbations discriminate an on target effect
WO2019178546A1 (fr) 2018-03-16 2019-09-19 Scipher Medicine Corporation Méthodes et systèmes de prédiction de la réponse à des thérapies anti-tnf
WO2019199945A1 (fr) * 2018-04-10 2019-10-17 Board Of Regents, The University Of Texas System Multimères d'antigènes codés par code barre et leurs procédés d'utilisation
MX2021004755A (es) 2018-10-26 2021-06-08 Alkahest Inc Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
JP2022541125A (ja) * 2019-06-27 2022-09-22 サイファー メディシン コーポレーション 患者を層別化するための分類子の開発
CN114302743B (zh) 2019-08-09 2024-05-14 弗劳恩霍夫应用研究促进协会 用于治疗关节炎的hla-dr/cii肽复合体
EP4038222A4 (fr) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
GB2622246A (en) * 2022-09-08 2024-03-13 Oncimmune Germany Gmbh Antibody assay
WO2024057793A1 (fr) * 2022-09-13 2024-03-21 国立大学法人信州大学 Peptide citrulliné pour la suppression de la métastase cancéreuse
CN122122462A (zh) * 2023-09-22 2026-05-29 默克专利有限公司 Tlr抑制剂治疗的生物标志物
WO2026020043A1 (fr) * 2024-07-17 2026-01-22 Laboratory Corporation Of America Holdings Biomarqueurs et procédés de mesure et de surveillance de l'activité d'une maladie inflammatoire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084249A2 (fr) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Utilisation therapeutique et diagnostique de profils de specificite d'anticorps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084249A2 (fr) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Utilisation therapeutique et diagnostique de profils de specificite d'anticorps

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LARCHE M.J., SACRE S.M., FOXWELL B.M: "Pathogenic role of TNF-alpha in rheumatoid arthritis", DRUG DISCOVERY TODAY. DISEASE MECHANISMS, vol. 2, no. 3, 2005, XP002521049 *
NELL V P K ET AL: "Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.", ANNALS OF THE RHEUMATIC DISEASES DEC 2005, vol. 64, no. 12, December 2005 (2005-12-01), pages 1731 - 1736, XP002521047, ISSN: 0003-4967 *
ROBINSON WILLIAM H ET AL: "Autoantigen microarrays for multiplex characterization of autoantibody responses.", NATURE MEDICINE MAR 2002, vol. 8, no. 3, March 2002 (2002-03-01), pages 295 - 301, XP002521048, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
US20080026485A1 (en) 2008-01-31
US20160146831A1 (en) 2016-05-26
WO2007123976A2 (fr) 2007-11-01
WO2007123976A3 (fr) 2008-12-11
EP2008100A2 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
DE602007009552D1 (de) Vorrichtung zur bestimmung der position eines aktuators
IL183718A (en) Method for measuring resistance or sensitivity to docetaxel
EP2042092A4 (fr) Capteur électrophysiologique
EP2076062A4 (fr) Capteur ultrasonore
EP2053413A4 (fr) Capteur
FR2874780B1 (fr) Capteur ultrasonore
EP2164280A4 (fr) Capteur acoustique
EP2076614A4 (fr) Anticorps synthetiques
EP2050397A4 (fr) Sonde ultrasonore
EP2448485A4 (fr) Capteur d'analytes
EP2011869A4 (fr) Nouvel anticorps anti-cd98
EP2014236A4 (fr) Sonde ultrasonique
EP2164281A4 (fr) Capteur acoustique
DE112007001418A5 (de) Mehrkammerultraschallsensor zur Bestimmung eines Flüssigkeitspegels
EP2000097A4 (fr) Sonde a ultrasons
DE602006017350D1 (de) Messung der thrombinaktivität in vollblut
EP2059299A4 (fr) Détermination de la variation dans le temps d'un paramètre médical d'un être humain
DE502007003402D1 (de) Strömungsmessvorrichtung zur bestimmung einer strömungsrichtung
DE602007000886D1 (de) Messinstrument für Oberflächenstrukturen
BRPI0819376A2 (pt) Sensores de umidade
EP2006379A4 (fr) Anticorps bispecifique hautement fonctionnel
DE602006009202D1 (de) Formmessgerät
EP1924122A4 (fr) Capteur ultrasonique
DE602006000455D1 (de) Sensormessfehler
DE602006017316D1 (de) Verfahrer zur Bestimmung eines Reibungsdrehmoment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081211

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GENOVESE, MARK

Inventor name: UTZ, PAUL J.

Inventor name: STEINMAN, LAWRENCE

Inventor name: ROBINSON, WILLIAM H.

Inventor name: HUEBER, WOLFGANG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GENOVESE, MARK

Inventor name: UTZ, PAUL J.

Inventor name: STEINMAN, LAWRENCE

Inventor name: ROBINSON, WILLIAM H.

Inventor name: HUEBER, WOLFGANG

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20091104BHEP

Ipc: G01N 33/53 20060101AFI20080124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091112

17Q First examination report despatched

Effective date: 20100115

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151103